This summary was created by AI, based on 2 opinions in the last 12 months.
The experts' reviews on Teva Pharmaceutical (TEVA-N) indicate a mixed sentiment. While one expert finds the stock cheap and with momentum, another expresses concerns over the sustainability of the share price appreciation and the company's large debt load. Overall, the reviews suggest that there is limited enthusiasm for the stock in its current state.
Massive share price appreciation not sustainable.
Large debt load presents difficulties.
Does not own shares.
Would not recommend buying at this time.
Doesn't offer growth. The stock is weak and will stay weak.
Teva Pharmaceutical is a American stock, trading under the symbol TEVA-N on the New York Stock Exchange (TEVA). It is usually referred to as NYSE:TEVA or TEVA-N
In the last year, 1 stock analyst published opinions about TEVA-N. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Teva Pharmaceutical.
Teva Pharmaceutical was recommended as a Top Pick by on . Read the latest stock experts ratings for Teva Pharmaceutical.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
1 stock analyst on Stockchase covered Teva Pharmaceutical In the last year. It is a trending stock that is worth watching.
On 2024-11-01, Teva Pharmaceutical (TEVA-N) stock closed at a price of $18.45.
It's cheap and has momentum, but that's all it has now. It never grabbed him.